Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease

Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Study ID
NCT02539849
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

FOS improve gut colonization by Faecalibacterium prausnitzii in patients with Crohn's disease

Key Dates

Start date
Dec 31, 2014
Status verified
Jan 2018
Primary completion
Dec 19, 2017
Completion
Dec 19, 2017

Study Design

Enrollment
38 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Other: adalimumab + FOS
    Adalimumab will be administered during 12 weeks in combination with daily FOS 6g. (FOS administration will start 2 weeks before Adalimumab)

Primary Outcome Measure

FOS increases counts of Faecalibacterium prausnitzii in faecal samples from Crohn's disease patients [ Time Frame: 14 weeks ]

Related Studies